Rodenburg C J, Cornelisse C J, Heintz P A, Hermans J, Fleuren G J
Cancer. 1987 Jan 15;59(2):317-23. doi: 10.1002/1097-0142(19870115)59:2<317::aid-cncr2820590225>3.0.co;2-4.
Tumor ploidy was determined by flowcytometry (FCM) in paraffin-embedded tissue of 74 patients with advanced ovarian cancer (International Federation of Gynecology and Obstetrics [FIGO] 2B, 3, 4). Significant differences in survival and progression-free survival were found between classes of tumor ploidy as well as for several clinical parameters, including FIGO stage, histologic grade, diameter of the largest metastases, presence of ascites, peritoneal carcinomatosis, and size of residual tumor. In a Cox regression analysis, tumor ploidy and presence or absence of ascites were the only significant factors for survival, whereas ascites and residual tumor proved to be the significant parameters for progression-free survival. Tumor ploidy was strongly associated with tumor bulk, size of residual tumor, and histologic grade. Tumor ploidy was the same within different tumor sites in the majority of the cases. On the basis of these findings tumor ploidy is considered to be a major prognostic factor for survival in advanced ovarian cancer.
采用流式细胞术（FCM）对74例晚期卵巢癌患者（国际妇产科联盟[FIGO]2B、3、4期）的石蜡包埋组织进行肿瘤倍体检测。结果发现，肿瘤倍体类别之间以及包括FIGO分期、组织学分级、最大转移灶直径、腹水、腹膜癌转移和残留肿瘤大小等几个临床参数之间，患者的生存率和无进展生存期存在显著差异。在Cox回归分析中，肿瘤倍体和腹水的有无是生存的唯一显著因素，而腹水和残留肿瘤则是无进展生存期的显著参数。肿瘤倍体与肿瘤体积、残留肿瘤大小和组织学分级密切相关。在大多数病例中，不同肿瘤部位的肿瘤倍体相同。基于这些发现，肿瘤倍体被认为是晚期卵巢癌生存的主要预后因素。
